Nanotechnology Now - Press Release: Nanoparticles Mimic Cholesterol Transporter and Attack Lymphoma

Home > Press > Nanoparticles Mimic Cholesterol Transporter and Attack Lymphoma

Abstract:
High-density lipoprotein (HDL) is well-known for its role in protecting the body from developing coronary artery disease, but HDL also helps lymphomas and other cancers acquire the large amounts of cholesterol they need to maintain the structure of their cell membranes as they grow rapidly. Researchers at Northwestern University have taken advantage of this dependency on HDL to create an HDL-mimicking nanoparticle that starves lymphoma cells of cholesterol, triggering them to commit programmed cell death without the use of any other anticancer agent.

Nanoparticles Mimic Cholesterol Transporter and Attack Lymphoma

Bethesda, MD | Posted on March 7th, 2013

C. Shad Thaxton, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern and member of the Northwestern University Center of Cancer Nanotechnology Excellence, and Leo Gordon, of Northwestern's Feinberg School of Medicine, led the team that developed this biomimetic HDL nanostructure. The investigators published their findings in the Proceedings of the National Academy of Sciences.

To create their biomimetic HDL nanostructures, the researchers start with spherical gold nanoparticles that are five nanometers in diameter and add the human protein ApoA1 and two phospholipids found in native HDLs. The gold nanoparticle serves two functions. First, it acts as a template that controls the shape and size of the biomimetic particles so that they recognize and bind tightly to a specific receptor, known as scavenger receptor type B-1 (SR-B1), which is expressed by lymphoma cells. Second, the gold core occupies the space that is normally filled by cholesterol esters, which thereby limits the ability of these particles to deliver cholesterol to the receptor-targeted lymphoma cells.

Initial experiments with lymphoma cells growing in culture showed that these nanoparticles are taken up by cells that have the target (SR-B1) receptor and have the desired effect of triggering programmed cell death, also known as apoptosis. They also demonstrated that apoptosis resulted from cholesterol flowing out of the cells. In contrast, the biomimetic HDL nanoparticles did not trigger cholesterol outflow from or apoptosis in normal human liver cells, macrophages, or lymphocytes.

Drs. Thaxton and Gordon and their collaborators then treated mice with human lymphomas with the biomimetic HDL nanoparticles. This treatment stopped tumor growth when the tumors were derived from lymphoma cells that expressed SR-B1, but had no effect on tumors derived from SR-B1 negative cells. The researchers note that because SR-B1 is not expressed in the majority of human tissue that the toxicity of these nanoparticles may be minimal compared to conventional chemotherapeutics.

####

About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: